Nov 09, 2020 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q2 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.
Jason D'souza - Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy
Welcome to Glenmark's Q2 earnings call. First, the review of operations for the quarter ended September 30, 2020. For the second quarter of FY 2021, Glenmark's consolidated revenue was at INR 29,524.79 million, recording an increase of 4.88%. For the 6 months ended September 30, 2020, Glenmark's consolidated revenue was at INR 52,972.66 million, recording an increase of 3.10%. India business, sales from the formulation business in India for the second quarter was at INR 10,506.91 million, recording growth of 17.22%. The India business continued to outperform the industry growth and has grown consistently over the past several years.
As per
Q2 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Nov 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers